Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours.

[1]  P. Kenemans,et al.  Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. , 1995, British Journal of Cancer.

[2]  M. Reddish,et al.  Does pregnancy immunize against breast cancer? , 1995, Cancer research.

[3]  J. Fagerberg,et al.  Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Fagerberg,et al.  Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. , 1995, Cancer research.

[5]  F. Hanisch,et al.  Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase from milk or mammary carcinoma cells. , 1995, European journal of biochemistry.

[6]  A. Sonnenberg,et al.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components , 1995, The Journal of cell biology.

[7]  J. Banchereau,et al.  Recent advances in the study of dendritic cells and follicular dendritic cells. , 1995, Immunology today.

[8]  J. Devitt.  Breast cancer: have we missed the forest because of the tree? , 1994, The Lancet.

[9]  M. Gross,et al.  N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts. , 1994, Cancer research.

[10]  A. Epenetos,et al.  Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer , 1994, Cancer.

[11]  R. Metzgar,et al.  Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. , 1994, Cancer research.

[12]  G. Riethmüller,et al.  Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma , 1994, The Lancet.

[13]  N. Tjandra,et al.  Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. , 1993, Cancer research.

[14]  L. Frati,et al.  Human B cell immune response to selected epitopes of the polymorphic epithelial mucin (PEM) in cancer patients. , 1993, In vivo.

[15]  S. Litvinov,et al.  The epithelial sialomucin, episialin, is sialylated during recycling. , 1993, The Journal of biological chemistry.

[16]  T. Irimura,et al.  Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. , 1993, Journal of immunology.

[17]  M. Kieny,et al.  Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[18]  K. Jerome,et al.  Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. , 1993, Journal of immunology.

[19]  C. Melief,et al.  Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. , 1993, Journal of immunology.

[20]  L. Frati,et al.  Human B-cell immune response to the polymorphic epithelial mucin. , 1993, Cancer research.

[21]  F. Itoh,et al.  Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis. , 1993, Immunology letters.

[22]  M. Ligtenberg,et al.  Cell membrane-associated mucins and their adhesion-modulating property. , 1992, Trends in biochemical sciences.

[23]  T. Duhig,et al.  Spatial and temporal expression of an epithelial mucin, Muc-1, during mouse development. , 1992, Development.

[24]  R. Bast,et al.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. , 1991, Cancer research.

[25]  N. Peat,et al.  Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. , 1990, The Journal of biological chemistry.

[26]  R. W. Baldwin,et al.  Immunological and structural features of the protein core of human polymorphic epithelial mucin. , 1990, Molecular immunology.

[27]  M. Ligtenberg,et al.  Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. , 1990, The Journal of biological chemistry.

[28]  I. Mckenzie,et al.  Glycosylation and the exposure of tumor-associated epitopes on mucins , 1990 .

[29]  M. Lan,et al.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Ligtenberg,et al.  Complexity of MAM-6, an epithelial sialomucin associated with carcinomas. , 1989, Cancer research.

[31]  C. Melief.  Dendritic cells as specialized antigen-presenting cells. , 1989, Research in immunology.

[32]  M. Larché,et al.  DEVELOPMENT OF ANTI-IDIOTYPIC ANTIBODIES AGAINST TUMOUR ANTIGENS AND AUTOANTIGENS IN OVARIAN CANCER PATIENTS TREATED INTRAPERITONEALLY WITH MOUSE MONOCLONAL ANTIBODIES , 1988, The Lancet.

[33]  S. Zotter.  Tissue and tumor distribution of human polymorphic epithelial mucin , 1988 .

[34]  J. Taylor‐Papadimitriou,et al.  Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. , 1987, Cancer research.

[35]  V. Zurawski,et al.  Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Bruning,et al.  MAM-6 antigen, a new serum marker for breast cancer monitoring. , 1986, Cancer research.

[37]  D. Hayes,et al.  Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. , 1985, The Journal of clinical investigation.

[38]  A. Sonnenberg,et al.  Monoclonal antibodies against human milk‐fat globule membranes detecting differentiation antigens of the mammary gland and its tumors , 1984, International journal of cancer.

[39]  J. Schlom,et al.  Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. , 1984, Hybridoma.

[40]  W. Bodmer,et al.  Monoclonal antibodies to epithelium‐specific components of the human milk fat globule membrane: Production and reaction with cells in culture , 1981, International journal of cancer.